Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HANDS HPV Vaccine Trial
PACTR202101499206800Phase 3Recruiting
- Sponsor
- Medical Research Council Unit The Gambia at LSHTM
- Start
- Jul 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection and cancer (5 arms), sponsored by Medical Research Council Unit The Gambia at LSHTM. Primary endpoint: Geometric mean titer non-inferiority across nine HPV types. Started Jul 2019; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectioncancer
Beyond the preview
Go deeper on PACTR202101499206800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202101499206800.